Mannitol therapy for children with cystic fibrosis: efficacy and safety

Author:

Simonova O. I.1ORCID,Gorinova Yu. V.2ORCID,Vysokolova O. V.3ORCID,Mukhina M. A.3ORCID,Yakushina E. E.3ORCID

Affiliation:

1. National Medical Research Center for Children’s Health; Sechenov First Moscow State Medical University (Sechenov University); Morozovsky Municipal Children Clinical Hospital

2. National Medical Research Center for Children’s Health

3. Morozovsky Municipal Children Clinical Hospital

Abstract

The article describes the mechanisms of mucostasis and lung damage in cystic fibrosis. Types of mucolytic therapy and importance of inhalation therapy are considered. The authors presented their own classification of mucoactive agents. The principle of action, advantages and efficacy of mucoactive drugs based on the mannitol molecule are discussed based on the results of multicenter randomized clinical trials, including those conducted in children with cystic fibrosis. The authors present their own experience in the use of mannitol at the Morozovsky Municipal Children Clinical Hospital and 42 BIDA tests for its tolerability, of which 38 tests were passed satisfactorily. We present various clinical cases demonstrating the failure of a tolerance test due to increased signs of respiratory failure (dyspnea), an example of a repeat test 8 months later with satisfactory results, the development of hemoptysis in a patient seen in the pulmonology department of the National Medical Research Center for Children’s Health. The case was described in an adolescent, and after mannitol inhalation was added to the existing basic therapy, there was a clear positive trend in flowmetry: FEV1-74% (a significant increase of 14%). Thus, the authors noted that mannitol is effective in children with cystic fibrosis over 6 years of age; its use is characterized by good compliance and general adherence to therapy due to convenience of use: no need for additional technical means to perform inhalation in the form of solutions outside the home and saving overall free time. An important observation noted by the authors is that the BIDA test should be performed in complete clinical and laboratory remission to obtain objective results.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference37 articles.

1. Kapranov N.I., Kashirskaya N.Y., Kondratieva E.I. Cystic fibrosis. 2nd ed. Moscow: Medpraktika-M; 2021. 680 с. (In Russ.) Available at: http://www.medpractika.ru/books/new/?id=316.

2. Boucher R.C. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Int Med. 2007;261(1):5–16. https://doi.org/10.1111/j.1365-2796.2006.01744x.

3. O’Sullivan B.P., Flume P. The clinical approach to lung disease in patients with cystic fibrosis. Semin Respir Crit Care Med. 2009;30(5):505–513. https://doi.org/10.1055/s-0029-1238909/.

4. Flume P.A., Robinson K.A., O’Sullivan B.P., Finder J.D., Vender R.L., WilleyCourand D.-B. et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009;54(4):522–537. Available at: https://pubmed.ncbi.nlm.nih.gov/19327189/.

5. Orlov A.V., Simonova O.I., Roslavtseva E.A., Shadrin D.I. M90 Mucoviscidosis (clinical picture, diagnosis, treatment, rehabilitation, dispensary). 2nd ed. St Petersburg: I.I. Mechnikov Northwestern State Medical University; 2014. 160 p. (In Russ.) Available at: http://ostrovaru.com/biblioteka/otdelnye-izdaniya/1192/.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3